Total Eradication of Metastatic Prostate Cancer with Radiation

Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation to the Prostate in de novo oligometaStatic prostate cancer (TERPS) trial

NIH-funded research University of Maryland Baltimore · NIH-11171437

This research explores whether using radiation to treat all known cancer spots in men with newly diagnosed, limited metastatic prostate cancer can prevent the disease from spreading further.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Maryland Baltimore NIH-funded
Lab location1 site (Baltimore, United States)
Project IDNIH-11171437 on NIH RePORTER

What this research studies

We are looking into whether radiation treatment for all visible cancer sites in men with newly diagnosed, limited metastatic prostate cancer can stop the disease from progressing. Previous work suggests that focused, high-dose radiation can improve outcomes and may even trigger an immune response against the cancer. This new opportunity aims to understand how radiation affects both visible and microscopic cancer cells. Our goal is to discover new ways radiation impacts the spread of cancer and potentially offer a new path to cure for these patients.

Who could benefit from this research

Good fit: Ideal candidates are men with newly diagnosed, castrate-sensitive prostate cancer that has spread to a limited number of locations (oligometastatic disease).

Not a fit: Patients with widespread metastatic prostate cancer or those who have already received extensive prior treatments for their metastatic disease may not benefit from this specific approach.

Why it matters

Potential benefit: If successful, this approach could offer a curative treatment option for men with newly diagnosed, limited metastatic prostate cancer by preventing further spread of the disease.

How similar studies have performed: Small randomized studies have shown success with similar radiation consolidation approaches in prostate cancer that has returned, but this is the first time it's being tested in newly diagnosed cases.

Where this research is happening

Baltimore, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Castrate sensitive prostate cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.